CJC-1295 No DAC (Mod GRF 1-29) 5mg

CJC-1295 No DAC — Proven Pulsatile GHRH Research Peptide 5mg

CJC-1295 no dac — also designated Modified GRF (1-29) or Mod GRF 1-29 — is a synthetic 29-amino-acid derivative of naturally occurring growth hormone-releasing hormone (GHRH), modified through four strategic amino acid substitutions that improve its metabolic stability without the albumin-binding Drug Affinity Complex present in the DAC-modified version. First characterised from studies in the early 1980s — when researchers established that the initial 29 amino acids of GHRH might retain the full functional properties of the complete 44-amino-acid native sequence — this peptide has become a foundational research tool in GH secretagogue biology. Supplied as a lyophilised powder in a single 5mg vial with a verified purity of >99% for in-vitro scientific research.

⚠️ Research Use Only. This product is intended exclusively for in-vitro scientific research. It is not approved for human or animal consumption, clinical use, or therapeutic application.

Table of Contents

1. Product Specifications
2. Historical Development and GRF Discovery
3. Four-Substitution Stabilisation
4. No DAC — Pulsatile GH Release Profile
5. Research Applications
6. Reconstitution and Storage
7. FAQ

Product Specifications

Historical Development and GRF Discovery

The research history of cjc 1295 without dac begins with the discovery of growth hormone-releasing factor (GRF) fragments in the early 1980s. At that time, researchers investigating the minimum functional sequence of GHRH established a landmark finding — the first 29 amino acids of the native 44-amino-acid GHRH sequence appeared to retain all the biological properties necessary to trigger GH release from pituitary somatotroph cells.

This discovery — that grf 1 29 represented the biologically active core of GHRH — established the GRF (1-29) sequence as the foundational structure for subsequent GHRH analogue development. The challenge that followed was pharmacokinetic: native GRF (1-29) was rapidly degraded by circulating proteases — particularly dipeptidyl peptidase-4 (DPP-4) — limiting its research utility.

Rigorous research over subsequent decades produced a stabilised, longer-lasting version — CJC-1295 No DAC — through strategic amino acid substitutions that resist the enzymatic cleavage sites responsible for native GRF degradation.

Four-Substitution Stabilisation

The defining structural feature of buy cjc-1295 no-dac mod grf 1-29 relative to native GRF (1-29) is the incorporation of four amino acid substitutions at positions particularly susceptible to proteolytic degradation.

These substitutions — which give the peptide its “Modified GRF (1-29)” designation — preserve the GHRH receptor binding affinity of the parent sequence while substantially reducing the rate of enzymatic degradation in research environments. The result is a peptide with a meaningfully extended functional research window compared to unmodified GRF (1-29) — making it a more practical and reproducible research tool for GH secretagogue biology.

The substitution approach differs fundamentally from the DAC modification strategy — where an albumin-binding chemical complex is added to achieve half-life extension. The cjc-1295 no dac mod grf 1-29 approach relies entirely on structural stabilisation through sequence modification rather than plasma protein binding.

No DAC — Pulsatile GH Release Profile

The absence of the Drug Affinity Complex is the defining pharmacokinetic feature of this compound — and the primary reason researchers select it over DAC-modified CJC-1295 for specific research protocols.

Without DAC, buy mod grf 1-29 preparations clear circulation in hours rather than days — producing an acute, pulsatile GH release that more closely mirrors the physiological pattern of endogenous GH secretion. Physiological GH is released in pulses — episodic bursts of GH secretion from the pituitary that are critical to downstream IGF-1 axis dynamics and the biological effects of GH across multiple tissue types.

Research protocols examining GH pulsatility, natural GH secretion patterns, or the physiological downstream effects of episodic GH release require a GHRH analogue that produces this pulsatile profile. CJC-1295 no dac is specifically the compound of choice for these protocols — whereas DAC-modified CJC-1295, with its sustained continuous stimulation profile, would be inappropriate for research requiring GH pulsatility preservation.

Research Applications

CJC-1295 No DAC is investigated within the following approved in-vitro research domains:

• Pulsatile GHRH receptor activation and GH secretion research
• GH axis physiology and natural secretion pattern investigation
• IGF-1 axis modulation under pulsatile GH stimulation
• Comparative no-DAC vs DAC pharmacokinetic research
• GH secretagogue receptor binding and activation studies
• Anabolic signalling pathway investigation
• Body composition and metabolic rate research
• Sleep architecture and neuroendocrine GH pulse research
• Synergistic blend research with GHS-R1a agonists (ipamorelin, GHRP-2)

Reconstitution and Storage

Reconstitute with sterile or bacteriostatic water. Add solvent slowly along the vial wall and allow to dissolve by gentle rotation. Do not shake or vortex. Store lyophilised powder at −20°C. Once reconstituted, maintain at 4°C and use within the timeframe specified by your research protocol. Protect from light and avoid repeated freeze-thaw cycles.

Explore additional GHRH analogue and GH secretagogue research compounds in our Anti-Age, Muscle Growth and Weight Loss research categories.

FAQ

What is CJC-1295 no DAC? CJC-1295 no DAC — also designated Modified GRF (1-29) or Mod GRF 1-29 — is a synthetic 29-amino-acid GHRH analogue stabilised through four strategic amino acid substitutions. It does not contain the Drug Affinity Complex albumin-binding modification of DAC-modified CJC-1295 — producing an acute, pulsatile GH release profile that more closely mirrors physiological GH secretion. Supplied as a 5mg lyophilised powder with >99% purity for in-vitro scientific research.

What is CJC 1295 without DAC used for in research? CJC 1295 without DAC is used in research protocols requiring pulsatile GHRH receptor activation — GH secretion patterns that mirror physiological GH pulsatility rather than sustained continuous stimulation. Research applications include pulsatile GH axis investigation, IGF-1 axis modulation under episodic GH stimulation, GHRH receptor binding studies, synergistic blend research with GHS-R1a agonists and comparative pharmacokinetic investigation against DAC-modified preparations.

What is the GRF 1 29 sequence and its significance? GRF 1 29 refers to the first 29 amino acids of growth hormone-releasing hormone — established in early 1980s research as the minimum functional fragment of GHRH capable of triggering GH release from pituitary somatotrophs. This discovery established the GRF (1-29) sequence as the structural foundation for GHRH analogue development. CJC-1295 No DAC / Modified GRF (1-29) is the stabilised research version of this foundational sequence.

Where can I buy CJC-1295 no DAC Mod GRF 1-29? Buy CJC-1295 no-dac mod grf 1-29 options are available through specialist research peptide suppliers. This compound is supplied strictly for in-vitro scientific research. It is not approved for human consumption, therapeutic use or clinical application. Researchers should ensure compliance with all applicable institutional and regulatory requirements.

How does buy mod grf 1-29 differ from buying CJC-1295 with DAC? Buy mod grf 1-29 provides a pulsatile, short-acting GHRH analogue with a half-life measured in hours — clearing rapidly and producing episodic GH release. CJC-1295 with DAC provides sustained, long-acting GHRH receptor engagement with a half-life of approximately 8 days through albumin binding. The choice is determined by whether the research protocol requires pulsatile or sustained GH axis stimulation.